The cost, which is confidential and was negotiated for a maximum of 300 million doses, is somewhat less than the $19.50 per shot the United States agreed to purchase a first shipment of 100 million doses of the identical vaccine, in series with what Reuters claimed in November.
The EU file dated Nov. 18 was circulated internally after the EU announced its supply offer with Pfizer and the German partner BioNTech of its on Nov. eleven.
The EU drug regulator is actually likely to determine on Monday on approval for the Pfizer vaccine after the photo was authorised in several countries, like Britain and the United States.
On Thursday Belgian say secretary for the budget Eva De Bleeker published on Twitter a table with prices Belgium will spend pharmaceutical companies for the COVID 19 vaccines of theirs. She retracted the post shortly after publishing.
In this table the Pfizer vaccine was suggested as costing Belgium 12 euros ($14.6) per dose, leading many to believe that was the entire price agreed with the EU.
Various other vaccines in the table were also shown with rates lower compared to rates disclosed by EU solutions.
“There is always a complete fee along with a cost upon delivery,” an EU official required in talks with vaccine creators told Reuters when made to clarify the difference between the Belgian and EU rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality needs, but pointed to what De Bleeker told the Belgian parliament last week. In this public hearing, De Beeker said Belgium’s budgeted costs were still partial.
Under EU prior purchase deals for COVID-19 vaccines, the bloc agrees upfront payments with businesses to secure doses before they’re approved. After approvals, EU governments are able to pay the rest to buy reserved doses.
The EU hasn’t revealed the initial payment agreed with Pfizer.
However, it mentioned in October that it paid aproximatelly 1 billion euros in downpayments to AstraZeneca, Sanofi and Johnson & Johnson for the shots of theirs, with an additional 1.45 billion euros budgeted for initial payments to Pfizer BioNTech, Curevac and Moderna.
It’s since agreed supply deals with all 6 corporations and it is negotiating a seventh arrangement with Novavax.